Aprea Therapeutics Presents Results From U.S. Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Amy Giles
Increasing Engagement

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition